MOLOGEN AG explains voting rights announcements of the new major shareholders

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Berlin, April 16, 2008 - The Berlin-based biotechnology company
MOLOGEN today explained voting rights announcements granted to the
company in March in accordance with Article 21 of the German
Securities Trading Act. After the off-market acquisition of a large
parcel of shares from Absolute Capital Management Holdings Ltd.,
Cayman Islands, and further share purchases via the stock market, the
Deutsche Ring Group holds a total of over 25% of the shares in
MOLOGEN AG in its companies Deutscher Ring Lebensversicherungs- AG,
Deutscher Ring Sachversicherungs- AG and Deutscher Ring
Krankenversicherungsverein a.G.

The Executive Board at MOLOGEN appeared very pleased and satisfied
about the intense commitment of the Deutsche Ring Group. "We are very
impressed with the faith that the Deutsche Ring Group has placed in
us with its long-term investment. It provides additional incentive
for us to push ahead with all our might with the development of
MOLOGEN and to notch up further successes", commented Dr. Schroff,
Chief Executive Officer of MOLOGEN. "We expect the speculation
regarding the parcel of shares held by Absolute Capital Management
Holdings to finally come to an end", added Chief Financial Officer
Petraß.

About MOLOGEN
MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes
in the research and development of innovative medicines based on DNA
structures (DNA: deoxyribonucleic acid).

Its patented DNA-based platform technologies MIDGE® and dSLIM® form a
universal foundation with a wide range of possible applications.
Activities focus on product developments for the treatment of cancer
and vaccines for serious infections in humans and animals.

MOLOGEN was founded in 1998 and was the first German biotechnology
company to go public. MOLOGEN AG shares are listed in the General
Standard of Deutsche Börse (ISIN DE 0006637200).

Disclaimer concerning prognoses
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future results
of business segments, financial classification numbers, developments
of the financial situation, or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking statements
as certain prognoses of actual future events and developments. The
company is neither responsible nor liable for these forward-looking
statements. It is not responsible for updating such information,
which only represents the state of affairs on the day of publication.

MOLOGEN AG
Fabeckstr. 30, 14195 Berlin, Germany
Contact: Joerg Petrass
Email: investor@mologen.com
Phone: +49-30-84 17 88-13
Fax: +49-30-84 17 88-50

--- End of Message ---

MOLOGEN AG
Fabeckstr. 30 Berlin Germany

WKN: 663720; ISIN:
DE0006637200;
Listed: Freiverkehr in Börse Berlin, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
General Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Stuttgart;